Atıf Formatları
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
  • IEEE
  • ACM
  • APA
  • Chicago
  • MLA
  • Harvard
  • BibTeX

H. C. Yildirim Et Al. , "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study," INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3, pp.258-265, 2024

Yildirim, H. C. Et Al. 2024. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3 , 258-265.

Yildirim, H. C., Kutlu, Y., Mutlu, E., Aykan, M. B., Korkmaz, M., Yalcin, S., ... Sakalar, T.(2024). The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3, 258-265.

Yildirim, Hasan Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study," INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3, 258-265, 2024

Yildirim, Hasan C. Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study." INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3, pp.258-265, 2024

Yildirim, H. C. Et Al. (2024) . "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study." INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.3, pp.258-265.

@article{article, author={Hasan Cagri Yildirim Et Al. }, title={The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study}, journal={INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY}, year=2024, pages={258-265} }